Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics, Inc. (TVRD)
Company Research
Source: GlobeNewswire
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its ?nancial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. Recent Highlights: Additional analysis from the REVERT IPF Phase 2 trial demonstrated that TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, as well as a 4.5-fold greater decline in IL-6, a central STAT3-driven
Show less
Read more
Impact Snapshot
Event Time:
TVRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVRD alerts
High impacting Tvardi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVRD
News
- Tvardi Therapeutics (TVRD) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium [Yahoo! Finance]Yahoo! Finance
- Tvardi Therapeutics (TVRD) had its "buy" rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.MarketBeat
- Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumGlobeNewswire
- Tvardi Therapeutics (TVRD) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
TVRD
Earnings
- 3/31/26 - Miss
TVRD
Sec Filings
- 4/1/26 - Form S-8
- 4/1/26 - Form POS
- 4/1/26 - Form 424B3
- TVRD's page on the SEC website